Abiomed to Showcase Impella 2.5 Advanced Circulatory Support Technologies at American College of Cardiology's Annual Scientific Sessions

Abiomed, Inc. (NASDAQ: ABMD) today announced the showcase of its advanced circulatory support systems including the Impella 2.5 at the American College of Cardiology’s (ACC) 56th Annual Scientific Sessions. ACC is the premier cardiovascular medical meeting, bringing together more than 30,000 cardiologists to further breakthroughs in cardiovascular medicine. The ACC Conference is being held in New Orleans from March 24-27. During ACC, the following presentations on Abiomed’s technology will be available. Dr. Karim Benali, Abiomed’s Chief Medical Officer, will present a poster entitled, "Percutaneous Circulatory Support During High Risk Angioplasty Procedures: A Multicenter Experience with Impella Technology,” on Sunday, March 25 at 9 AM. Dr. Melchior Seyfarth will present during the "Late-Breaking Emerging Technologies and Innovations,” on the Impella 2.5. The session is scheduled for Sunday, March 25 at 2:30 PM. Drs. Krischan D. Sjauw, Maurice Remmelink, Jan Baan, Jr., René J. van der Schaaf, Marije M. Vis, Karel T. Koch, Jan G. Tijssen, Jan J. Piek, Robbert J. de Winter, and José P. Henriques will present "Preliminary Experience of the MACH 2 Trial: Safety and Feasibility of Left Ventricular Support With the Impella Recover LP 2.5 Device in Patients With Acute ST-Segment Elevation Myocardial Infarction,” on Monday, March 26 at 7:15 AM. This presentation will also be available as poster on Monday, March 26 at 2:00 PM. "We look forward to providing more data on the European experience with the Impella 2.5 during high-risk angioplasty as well as a sample analysis of the Impella performance for patients suffering from a heart attack,” said Michael R. Minogue, Chairman, CEO and President of Abiomed. "I am looking forward to sharing the performance of the Impella 2.5 on patients suffering from an acute event such as a heart attack. I have already published data on its safety and effectiveness during high-risk angioplasty and look forward to continued use of this technology,” said Dr. J.P.S. Henriques, Cardiologist at the Academic Medical Center in Amsterdam. ABOUT ABIOMED Based in Danvers, Massachusetts, Abiomed, Inc., is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. Abiomed currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. The Company also developed the AbioCor® Implantable Replacement Heart. In Europe, Abiomed offers the Impella® LP2.5, Impella® LP5.0, Impella® LD, the Impella® RD and an Intra-Aortic Balloon under CE Mark approval. The Impella® 5.0 and 2.5 are investigational devices limited by Federal Law solely to investigational use in the United States. Other Impella devices and the iPulse™ combination console system are not yet available for sale in the United States. For additional information please visit: www.abiomed.com. FORWARD-LOOKING STATEMENTS This Release contains forward-looking statements, including statements regarding development of Abiomed’s existing and new products, the Company’s progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.